Selective antibody removal from blood, plasma and buffer using hollow fiber-based specific antibody filters

Therapeutic antibody removal is performed to facilitate ABO-incompatible kidney transplants and heart and kidney xenotransplants, and to treat Goodpasture syndrome, myasthenia gravis, hemophilia with inhibitors, and thrombocytopenic purpura. Antibody removal is achieved non-selectively, via plasma exchange, or semi-selectively, via plasma perfusion through immunoadsorption columns containing immobilized protein A. We are developing hollow fiber-based specific antibody filters (SAFs) that selectively remove antibodies of a given specificity directly from whole blood, without separation of the plasma and cellular blood components and with minimal removal of plasma proteins other than the targeted antibodies. The working unit of the SAF is a hollow fiber dialysis membrane with antigens, specific for targeted antibodies, immobilized on the inner fiber wall. Several thousand SAF fibers are connected in parallel to produce a filter similar in construction to a hollow fiber hemodialyzer. A principal goal of our research is to identify the primary mechanisms that control antibody transport within the SAF, and to use this information to guide the choice of design and operational parameters that maximize the SAF-based antibody removal rate. We approached this goal by formulating a simple mathematical model of SAF-based antibody removal and performing in vitro antibody removal experiments to test key predictions of the model. Our model revealed three antibody transport regimes, defined by the magnitude of the Damkohler number Da (antibody-binding rate/antibody diffusion rate): reaction-limited (Da ≤ 0.1), intermediate (0.1 < Da < 10), and diffusion-limited (Da ≥ 10). For a given SAF geometry, blood flow rate, and antibody diffusivity, the highest antibody removal rate was predicted for diffusion-limited antibody transport. We performed in vitro antibody removal experiments in which SAFs containing immobilized bovine albumin (BSA) were used to remove anti-BSA antibodies from buffer. The measured anti-BSA removal rates were consistent with antibody transport in the intermediate regime. We concluded that initial SAF development work should focus on achieving diffusion-limited antibody transport by maximizing the SAT antibody-binding capacity. If diffusion-limited antibody transport is achieved, the antibody removal rate can be raised further by increasing the number and length of the SAF fibers and by increasing the blood flow rate through the SAF.